Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri DSM 12246
- Development stage
- Preclinical
- Lead developer
- Royal DSM
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
lactobacillus reuteri DSM 12246 is a specific probiotic bacterial strain of *Lactobacillus reuteri* investigated as an orally administered live microbial therapeutic for acute pediatric infectious diarrhea and gastroenteritis. In the published clinical studies provided, it was developed and tested in combination with *Lactobacillus rhamnosus* 19070-2 rather than as a clearly characterized monotherapy product, and the combination shortened diarrhea duration and reduced persistent loose stools, with the greatest benefit when given early in the diarrheal course. Its therapeutic rationale is microbiome-based rather than receptor-targeted: as a live biotherapeutic/probiotic organism, it is intended to modulate the intestinal microbial environment, inhibit enteric pathogens, and support restoration of gut homeostasis. Public-source support here is limited to peer-reviewed publications; no specific commercial brand, sponsor pipeline asset, or manufacturer for DSM 12246 alone is identified in the provided evidence.
- Other names
- lactobacillus reuteri DSM 12246
Beyond the preview
Go deeper on lactobacillus reuteri DSM 12246.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri DSM 12246.